The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Myocarditis | NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram
YouTube LinkedIn Prepare to become a physician, build your knowledge, lead a health care …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Myocarditis is an inflammatory disease of the heart that may occur because of infections,
immune system activation, or exposure to drugs. The diagnosis of myocarditis has changed …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Importance Limited information is available on the safety of a rechallenge with an immune
checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective To identify …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Twelve regulated cell death programs have been described. We review in detail the basic
biology of nine including death receptor-mediated apoptosis, death receptor-mediated …

Fulminant myocarditis (FM) is an uncommon syndrome characterized by sudden and severe
diffuse cardiac inflammation often leading to death resulting from cardiogenic shock …